• 1. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 2. Fe3O4@PANI: a magnetic polyaniline nanomaterial for highly efficient and handy enrichment of intact N-glycopeptides??
  Zhizhen Lai,Mo Zhang,Jinyu Zhou,Tianjing Chen,Dan Li,Xuejing Shen,Jia Liu,Jiang Zhou,Zhili Li Analyst, 2021,146, 4261-4267
• 3. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 4. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 5. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Primary amines

Recent Advances in the Study of 2-(3-Methylcyclobutyl)ethan-1-amine (CAS: 1694374-22-5) in Chemical Biology and Pharmaceutical Research

The compound 2-(3-Methylcyclobutyl)ethan-1-amine (CAS: 1694374-22-5) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This research brief aims to provide an overview of the latest findings related to this compound, focusing on its synthesis, biological activity, and potential as a drug candidate. Recent studies have highlighted its role in modulating specific biological pathways, making it a promising target for further investigation.

One of the key areas of interest is the synthesis and optimization of 2-(3-Methylcyclobutyl)ethan-1-amine. Researchers have developed novel synthetic routes to improve yield and purity, which are critical for its application in drug development. Advanced techniques such as asymmetric catalysis and green chemistry approaches have been employed to address challenges in its production. These advancements not only enhance the scalability of the compound but also reduce environmental impact, aligning with the growing emphasis on sustainable pharmaceutical manufacturing.

In terms of biological activity, recent in vitro and in vivo studies have demonstrated that 2-(3-Methylcyclobutyl)ethan-1-amine exhibits significant interactions with certain neurotransmitter receptors, particularly those involved in the central nervous system (CNS). This has led to speculation about its potential use in treating neurological disorders such as depression, anxiety, and neurodegenerative diseases. Preliminary data suggest that the compound may act as a modulator of serotonin and dopamine pathways, although further mechanistic studies are required to confirm these findings.

Another promising avenue of research involves the compound's potential as a building block for more complex pharmaceutical agents. Its unique cyclobutyl moiety offers structural diversity that can be leveraged to design new molecules with enhanced pharmacological properties. Several research groups have reported the successful incorporation of 2-(3-Methylcyclobutyl)ethan-1-amine into larger scaffolds, resulting in compounds with improved binding affinity and selectivity for target proteins. These developments underscore its versatility in medicinal chemistry.

Despite these encouraging results, challenges remain in the development of 2-(3-Methylcyclobutyl)ethan-1-amine as a therapeutic agent. Issues such as bioavailability, metabolic stability, and potential toxicity need to be addressed through comprehensive preclinical studies. Recent efforts have focused on optimizing the pharmacokinetic profile of the compound, with some studies exploring prodrug strategies to enhance its delivery and efficacy. Collaborative research between academia and industry will be essential to overcome these hurdles.

In conclusion, 2-(3-Methylcyclobutyl)ethan-1-amine (CAS: 1694374-22-5) represents a compelling area of research in chemical biology and pharmaceutical science. Its unique structural features and promising biological activity make it a valuable candidate for further exploration. Continued advancements in synthesis, mechanistic understanding, and drug design will be crucial to unlocking its full therapeutic potential. This brief highlights the importance of interdisciplinary collaboration and innovation in driving progress in this field.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)